ALLERNIX MULTI SYMPTOM DIN 02369656
Health Canada record
| Active ingredient(s) | DESLORATADINE 5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | NON-PRESCRIPTION DRUGS |
| Class | Human |
| ATC | R06AX27 DESLORATADINE |
| Original market date | 31-Jan-2012 |
| Current status date | 11-May-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DESLORATADINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02247192 | AERIUS | BAYER INC | Syrup | DESLORATADINE 0.5 MG | Approved |
| 02243919 | AERIUS | BAYER INC | Tablet | DESLORATADINE 5 MG | Marketed |
| 02247193 | AERIUS KIDS | BAYER INC | Syrup | DESLORATADINE 0.5 MG | Marketed |
| 02309300 | AERIUS SINUS + ALLERGY | BAYER INC | Tablet (Extended-Release) | DESLORATADINE 2.5 MG; PSEUDOEPHEDRINE SULFATE 120 MG | Marketed |
| 02415771 | ALLERGY CONTROL DESLORATADINE | PHARMASCIENCE INC | Tablet | DESLORATADINE 5 MG | Approved |
| 02546019 | DESLORATADINE | JAMP PHARMA CORPORATION | Tablet | DESLORATADINE 5 MG | Marketed |
| 02298155 | DESLORATADINE ALLERGY CONTROL | PHARMASCIENCE INC | Tablet | DESLORATADINE 5 MG | Marketed |
| 02377195 | AERIUS DUAL ACTION 24 HOUR | BAYER INC | Tablet (Immediate- And Extended-Release) | DESLORATADINE 5 MG; PSEUDOEPHEDRINE SULFATE 240 MG | Cancelled Pre Market |
| 02408740 | DESLORATADINE ALLERGY CONTROL | DOMINION PHARMACAL | Tablet | DESLORATADINE 5 MG | Cancelled Post Market |
| 02338424 | DESLORATADINE TABLETS | APOTEX INC | Tablet | DESLORATADINE 5 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14303 | 2013-04-17 | Abbreviated New Drug Submission (ANDS) | Manufacturer name change |
| 12468 | 2011-06-30 | Abbreviated New Drug Submission (ANDS) |
International API supply for DESLORATADINE
11 valid EDQM Certificates of Suitability from 11 holders. 11 active FDA Drug Master Files.
Request a quote for ALLERNIX MULTI SYMPTOM